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Summary: We performed restriction analysis and Southern blotting of the muscle mitochondrial DNA from
34 patients suffering from different myopathies. In 13/21 patients with chronic progressive external ophthal-
moplegia the muscle mitochondrial DNA was shown to be heteroplasmic. Further mapping by use of several
restriction enzymes yielded large deletions in muscles from 10/13 chronic progressive external ophthalmoplegia
patients. Most of the deletions spanned large parts of the mitochondrial genome, leading to loss of mito-
chondrial genes encoding several subunits of the respiratory chain complexes I (NADH-dehydrogenase), IV
(cytochrome c oxidase) and V (ATP-synthetase), as well as of several tRNAs.
Comparison of the mapping data with the histochemical and biochemical results did not provide a clear
correlation between the location of the mitochondrial genetic defects and the functional deficiencies of the
affected respiratory chain complexes.
In the majority of patients with chronic progressive external ophthalmoplegia, but without a family history
of the disease, restriction analysis reveals large mutations of the mitochondrial genome, while other methods
are necessary for the localization of defects in all cases with maternal transmission of the disease. The same
holds true for all other kinds of mitochondrial myopathies based on defects within the nuclear DNA or on
derangements of the "cross-talk" between the nuclear and the mitochondrial genomes.
Introduction - j- f * r ^ity of the resulting diseases can range from only slight
The most important function of mitochondria is the and discrete forms to those with a lethal outcome,
production of energy in the form of ATP by oxidative The variability of the diseases often renders the dif-
phosphorylation via the respiratory chain. As this is ferential diagnosis difficult. In most congenital or
an essential requirement for the survival and health infantile forms of the mitochondrial disorders the
of nearly all cells, defects in the energy providing leading symptom is lactic acidosis due to an interrup-
machinery of the mitochondrion lead to disease. De- tion of substrate utilisation within the mitochondrion,
pending on the number of affected cells, the type of Usually the predilection locus of the disease is the
organ and the affected metabolic pathway, the sever- skeletal muscle, leading to a classification of these
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forms as mitochondrial myopathies. In adult forms,
discrete parts of the central nervous system are fre-
quently affected and neuromuscular symptoms are
the first indicators. Therefore as an important diag-
nostic step a muscle biopsy is taken and the tissue is
subjected to histological, histochemical, electron mi-
croscopical and biochemical investigations.
Recently Holt, Harding & Morgan-Hughes (1) discov-
ered a new diagnostic approach when they found
deletions of the mitochondrial DNA (mtDNA) in
some patients with mitochondrial myopathies. The
five respiratory chain complexes are composed of 69
polypeptide subunits, 13 of them encoded by the
mitochondrial genome. Since many metabolic path-
ways are also located specifically within the mito-
chondrion, the potential number of defects at different
sites within the mitochondrion is very large. Thus a
detailed classification of the diseases requires the ap-
plication of many different methods. On the other
hand, the amount of muscle tissue usually obtained
by biopsy is very limited. Therefore, in order to in-
crease the probability of defect localisation, an ade-
quate diagnostic strategy is necessary, which takes
account of the different diagnostic valencies of the
methods used.
Here we describe restriction fragment analysis of mus-
cle biopsies from 34 patients with different myopa-
thies, and the results are compared with the histo-
chemical and biochemical data. In some cases gen-
omic Southern blotting was also performed in cultured
fibroblasts from affected patients. In addition, we
have developed a scheme for an efficient diagnostic
procedure for mitochondrial myopathies, taking into
account the work so far reported on mtDNA deletions
(1-12,38).
Materials and Methods
Patients
The 34 patients were divided into four groups.
Group 1 (patients 1 — 5 of tab. 1) consisted of 5 patients suf-
fering from typical Kearns-Sayre syndrome, i.e. chronic pro-
gressive external ophthalmoplegia, pigmentary retinopathy,
heart block and at least one of the following symptoms: limb
weakness, ataxia and/or other neurological symptoms.
Group 2 (patients 6 — 21 of tab. 1) consisted of 16 patients with
ocular myopathy including ptosis and ophthalmoplegia; most
of them had an additional symptom like limb weakness, ataxia
and/or peripheral neuropathy.
Group 3 (patients 22 — 26 of tab. 1) consisted of 5 patients with
histochemically and biochemically defined mitochondrial myo-
pathies; all had lactic acidosis; one had mitochondrial ence-
phalomyopathy with lactic acidosis and stroke-like episodes
(patient 22); 2 had fatal infantile cytochrome c oxidase defi-
ciency (patients 23, 24); one had a combined complex I and IV
deficiency (patient 25), and one (patient 26) had muscular
carnitine deficiency.
Tab. 1. Clinical data of patients with chronic progressive external ophthalmoplegia (group 1, 2)
Patient no.
Group 1
1
2
3
4
5
Group 2
6
7
8
9
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14
15
16
17
18
19
20
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23
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Age of
onset
(a)
13
20
30
17
11
17
21
20
30
12
28
58
55
16
37
18
19
42
68
11
62
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For all patients of groups 1, 2 and 3, histological examination
of skeletal muscle revealed ragged red fibers.
Group 4 consisted of 8 patients (not shown in tab. 1) suffering
from different forms of degenerative myopathies. None of them
had chronic progressive external ophthalmoplegia or ragged
red fibers in their skeletal muscle; no histochemical/biochemical
respiratory chain complex deficiency was observed.
Muscle b iopsy and morphology
Muscle biopsies (approximately 750 mg wet weight per biopsy)
were obtained from patients under local anaesthesia. For his-
tochemical analysis muscle specimens were immediately frozen
in isopentane cooled in liquid nitrogen. Histological and his-
tochemical routine procedures included a modified Gomori tri-
chrome stain and reactions for NADH-tetrazolium reductase
(complex I), succinate dehydrogenase (complex II), cytochrome
c oxidase (complex IV) and mitochondrial ATP-synthetase
(complex V) (13).
Muscle homogenate
Frozen muscle was homogenized with 29 volumes of 50 mmol/1
TRIS-HC1, pH 7.4 containing 150 mmol/1 KC1 and 1 mmol/1
EDTA by use of a glass/glass homogenizes The homogenate
was filtered through two layers of cheese cloth to remove
connective tissue (14).
Biochemis t ry
Activities of NADH-cytochrome c oxidoreductase were meas-
ured spectrophotometrically in muscle homogenates as de-
scribed by Hatefi & Rieske (15). The activity of complex I 4- III
was determined as the antimycin A and rotenone sensitive
fraction of total NADH-cytochrome c oxidoreductase in the
presence of antimycin A (5 mg/1) and rotenone (5 mg/1). Suc-
cinate-cytochrome c oxidoreductase (complex II 4- III) was
measured as described by Tisdal (16), succinate dehydrogenase
(part of complex II) as described by Hatefi & Stiggal (17), and
cytochrome c oxidase (complex IV) as described by Wharton
& Tzagaloff (18). Citrate synthase was measured as described
by Sheperd & Garland (19) in the presence of 40 ml/1 Triton.
DNA analys is
Proteinase K, restriction enzymes and the nick-translation kit
were from Boehringer Mannheim, [oc32P]dCTP (111 TBq/mmol
= 3000 Ci/mmol) from NEN and Hybond C filters were from
Amersham, Germany. Agarose was from Bethesda Research
Laboratories (BRL), and chemicals were from Sigma or from
Merck, Germany.
The DNA from 30 — 50 mg of tissue was extracted by overnight
digestion with 200 mg/1 of proteinase K in 1 ml of 10 mmol/1
Tris-HCl, pH 8.0, 400 mmol/1 NaCl, 2 mmol/1 EDTA, 2 g/l SDS
at 37 °C. DNA was recovered by extraction with phenol,
phenol/chloroform, precipitated with 2 volumes of ethanol and
100 mmol/1 NaCl, and dissolved in 60 μΐ of 25 mmol/1 Tris-
HCl, l mmol/1 EDTA pH 8.O.
DNA (0.5 μg) was digested with the endonucleases BamHI,
Pvull, PstI, HindUI, Hpal, EcoRV, Xbal, Kpnl and Avail as
described (20), then separated by electrophoresis (8 V/cm for
5 h) on an 8 g/1 agarose gel, stained with 0.1 mg/1 ethidium
bromide for 15 min and subjected to Southern blotting.
The mitochondrial DNA probes used for hybridization are
described in detail elsewhere (12).
Results and Discussion
Preliminary Remarks
Besides its nuclear genome the cell contains up to several
thousand copies of the mtDNA. The mitochondrial genome is
double-stranded and circular, unlike the nuclear DNA, which
is linear. The 16569 base pair mtDNA constitutes genes that
code for 13 subunits of the respiratory chain complexes, 22
tRNAs and 2 rRNAs (22). As compared with nuclear DNA,
the mitochondrial genome has a highly compact structure con-
sisting almost entirely of coding regions (fig. 1), and it uses its
own genetic code. It is inherited exclusively from the mother
and can segregate during mitotic growth. Mitochondrial DNA
shows a high mutation rate, yet encodes highly conserved pro-
teins. Because of these traits, analysis of the mtDNA mutations
has yielded new insights into the inheritance and the appearance
of some neuromuscular defects (23).
OH
Cytochrome b.
ND4
ND4L
Arg
ND3
Gly
Cytochrome c oxidase III
Cytochrome c oxidase I
Asp
Cytochrome c oxidase 0
ATPase subunit 6/8
Fig. 1. Mitochondrial DNA according to 1. c. (22, 23)
The map represents the heavy (H) and light (L) strands
of the circular mitochondrial genome bearing the genes
(solid areas) for the subunits of NADH-dehydrogenase
(complex I, NDj to ND6), cytochrome c oxidase I, II
and III, ATP-synthetase 6 and 8 (ATPase 6/8) and
cytochrome b. The D-loop region and the genes for the
small and larger ribosomal RNAs as well as for 22
tRNAs are given as open areas as indicated. OH, OL are
the origins of replication for the heavy and light strand,
respectively; PHi, Pm, PL mark the respective promo tors
for the initiation of the heavy and light strand transcrip-
tion.
Mitochondrial encephalomyopathies are a clinically heteroge-
nous group of neurological disorders characterized histologi-
cally by the "ragged red fibres" in muscle. The clinical features
include infantile lactic acidosis, Leigh syndrome, chronic pro-
gressive external ophthalmoplegia, exercise-induced myopathy
and other multisystem disorders. Affection of the central nerv-
ous system causes various symptoms like ataxia, blindness,
dementia, seizures and stroke-like episodes. Also other organs
(heart, kidney, endocrine system) can be affected (24).
Histochemically or biochemically characterized defects of dif-
ferent parts of the respiratory chain are found in the majority
of patients with mitochondrial myopathy. As about 20% of the
patients have affected relatives and maternal transmission is
much more frequent than paternal transmission it has been
suggested that these disorders may be caused by mutation of
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the mitochondrial genome. Using genomic Southern analysis,
Holt et al. (1) recently published the first description of deletions
of the mtDNA in some forms of mitochondrial myopathies. In
the meantime their results have been confirmed by other groups,
including our own (3 — 12).
Treatment of extracted muscular DNA with restriction endo-
nucleases such as Pvull or BamHl, which have only one rec-
ognition site in the chronic progressive external ophthalmople-
gia genome, usually linearize the mtDNA, resulting in a single
band in Southern blots. A possible interference of "mitochon-
drial" sequences within the nuclear genome can be obviated by
short exposure times for the autoradiography, since only high
copy number sequences are observable after short time exposure
(4). Thus treatment with "single cutter" restriction enzymes and
hybridization with labelled total human mtDNA can yield the
following patterns (fig. 2A):
— only one single band of expected length, if the genome has
no larger deletions, insertions or duplications (fig. 2A, patient
15);
— one faster migrating, i. e. smaller DNA, if all mitochondrial
genomes are deleted and the deletion is outside the restriction
site of the single cutter enzyme;
23.1 -
9.46-
6.56-
436-
2.32-
2.02-
TB
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DNA
size
[103 bases]
-23.1
- 9Λ6
6.56
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Patient no.15 10 3 5 7 9 10 13
Fig. 2. Autoradiogram of a genomic Southern blot hybridiza-
tion of muscle mitochondrial DNA from selected pa-
tients.
Numbering of patients is the same as in table 1.
A: restriction pattern after digestion with the single
cutter enzyme BamHl;
patient 15: only one band of expected size;
patient 10: two bands (mtDNA heteroplasmy), one
of expected size and one faster migrating smaller
band;
patient 3: one band of expected size and one slower
migrating band. Further mapping of the mitochon-
drial genome of patient 3 revealed that the BamHl
restriction site was within the deleted part of the
genome.
B: restriction pattern after digestion with Pstl, which
has two restriction sites within the mitochondrial
genome (positions 6910 and 9020); digestion of an
intact mitochondrial genome therefore results in two
bands, 14487 and 2110 bases in length. Patients 4,
5, 7, 9, 10 and 13: two bands of expected size with
one additional slower migrating band, which dem-
onstrates a deletion in the large restriction fragment.
All hybridizations were done using a labelled, nearly
full length mtDNA as a probe (12). Marker sizes (in
103 bases) are shown at left and right.
— two bands, one of expected size and one more rapidly
migrating band, if there are two DNA populations (hetero-
plasmy) but the restriction site for the single cutter enzyme is
not deleted (fig. 2A, patient 10);
— two bands, one of expected size and one slower migrating,
if there is mtDNA heteroplasmy and the deletion spans either
the restriction site of the single cutter enzyme, resulting in a
non-linearized mtDNA population, or there is an insertion
within the genome (fig. 2A, patient 3).
Results
Restriction analysis
Genomic Southern blotting in 34 patients with differ-
ent myopathies was performed. When the restriction
enzymes, BamHl and Pvull, were used to digest mus-
cular DNA from the 13 patients of group 3 and 4,
followed by Southern analysis, a single band of the
expected size was found. Thus, there was no mutation
involving a lengthy sequence of DNA, i. e. no deletion
or insertion, in the muscular mtDNA of these pa-
tients. Similarly, no mtDNA deletions were detected
in fibroblast cultures from the patients of group 3.
DNA samples from all patients of group 3 and 4 were
therefore not further investigated. Hybridisation anal-
ysis, after digestion with BamHl and Pvull of the
muscular DNA from the 21 patients of group 1 and
2, showed in 13/21 a pattern consistent with two
mtDNA populations (mtDNA heteroplasmy); one
band corresponded to full-length molecules of
mtDNA, while the other, more rapidly migrating
band corresponded to smaller, deleted mtDNA. This
pattern was found in all 5 patients with the typical
Kearns-Sayre triad (25) (group 1) and in 8/16 in group
2. The remaining 8 patients of group 2 showed a
normal pattern and were therefore excluded from
further mapping. We cannot exclude however that
there were small deletions or even point mutations in
these 8 patients. Ten of the 13 patients of group I and
II with mitochondrial heteroplasmy were further
mapped, using a set of different restriction enzymes
(fig. 2B). The site and size of the deletions within the
mutated mitochondrial genome are further demon-
strated in figure 3. All deletions affected parts of the
genes coding for the subunits of complex I of the
respiratory chain, and in 9/10 cases the genes for
complex IV and V subunits were also involved. In
one case only (patient 4 of tab. 1), the gene for
cytochrome b (the only mitochondrially encoded com-
plex III subunit) was also affected. In 8 of the 10
mutated mitochondrial genomes (fig. 3) deletion starts
within the ATPase 6/8 subunit region, extending to
the ND5/6 region. Recently, two independent groups
(26, 27) demonstrated an identical deletion in Kearns-
Sayre patients. Sequence analysis revealed break-
points at position 8482 within the ATPase 8 gene and
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Fig. 3. Localization of mitochondrial DNA deletions in pa-
tients with Kearns-Sayre syndrome (group 1) and with
ocular myopathy (group 2).
The maps at the top represent the heavy (upper map)
and light (lower map) strands of the linearized mtDNA.
Symbols are the same as in fig. 1.
Intact regions of the mitochondrial genome are shown
as solid areas; the regions of uncertainty as obtained by
restriction mapping (12) are indicated as hatched areas;
the deletions are given within the dotted lines.
at position 13446 within the ND5 gene. This region
is flanked on both sites by a perfect 13 base pair
repeat. The 4977 base pair-long deletion spanned one
of the repeats. This implies that genomic deletions
may arise from homologous recombination in mam-
malian cells, as already found for other eukaryotic
cells (26).
Histochemistry
A detailed discussion of the extent to which the ob-
served deletions are reflected by histochemical and
biochemical measurements in muscle is given else-
where (12). Here we refer to the diagnostic value of
the different methods used. In brief, histochemically
we found normal complex II activities in all muscle
fibres (not shown in tab. 1), while on the other hand
focal deficiency of complex IV was found in all 13
patients with mitochondrial DNA deletions, although
in partient 3 (tab. 1) the deletion did not affect mi-
tochondrial complex IV and V genes. Mitochondrial
ATP-synthetase was measured histochemically only
in 6 out of 13 patients with deleted mitochondrial
genomes and was found to be diminished in 4/6.
In 8 of 21 patients with chronic progressive external
ophthalmoplegia no large mtDNA deletions were ob-
served. Histochemical determinations were performed
in 5 of these 8 patients and cytochrome c oxidase
deficiency was found in all 5 patients, while ATPase
deficiency was observed in 2/5. Cytochrome c oxidase
deficiency was also found histochemically in 4 out of
5 patients of group 3.
Biochemistry
Biochemical activities of NADH-cytochrome c oxi-
doreductase (complex I + III), succinate-cytochrome
c oxidoreductase (II + III) and cytochrome c oxidase
(IV) were determined in 7 out of 13 patients with
deleted mtDNA. Although the deletions in all 7 pa-
tients affected parts of the complex I genes this genetic
situation was reflected by biochemical measurements
of complex I + III activities only in 4/7 patients. One
patient (No. 1) had decreased complex II + III activ-
ity in his muscle, but he had no deletion of the
cytochrome b gene. Another patient (No. 4) with a
mutated cytochrome b gene exhibited normal complex
II activities biochemically as well as histochemically.
Only 5/7 patients with a mitochondrial DNA deletion
spanning at least parts of the three complex IV genes
also had a biochemically deficient cytochrome c oxi-
dase activity in their muscle homogenates.
Discussion
Similar results (i. e. no clear cut correlation between
site and size of the mtDNA deletions at one site and
the loss of biochemically measured enzyme activities
as well as the severity of the disease at the other site)
have also recently been published by other groups (4,
7, 38). The possible reasons for this lack of a clear
correlation are discussed in detail elsewhere (12).
So far, 89 patients with mitochondrial myopathies
have been described in the literature (1 — 12, 38),
whose mitochondrial DNA exhibits lengthy deletions
(tab. 2). All of these had chronic progressive external
ophthalmoplegia and all had two populations of
mtDNA in their muscle mtDNA (heteroplasmy), with
the exception of reference (5).
Taking the results reported so far in the literature
(tab. 2) together with our present work, the following
conclusions can be drawn.
First, lengthy deletions of the mitochondrial genome
were found exclusively in patients with chronic pro-
gressive external ophthalmoplegia. Out of 52 patients
with the typical Kearns-Sayre triad reported so far,
46 had a mitochondrial heteroplasmy and a popula-
tion of deleted mtDNA. Poulton et al. (8) reported
heteroplasmy and large duplications (about 8000
bases) of the mitochondrial DNA in several tissues of
two patients with chronic progressive external
ophthalmoplegia. Thus restriction analysis of the mi-
tochondrial genome shows lengthy deletions in about
90% of Kearns-Sayre patients and about 44% of all
cases with chronic progressive external ophthalmo-
plegia (tab. 2).
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Tab. 2. Localization of mtDNA deletion and histochemical/biochemical data (group 1, 2, 3)
Patient no. mtDNA deletions
Map coordinates Affected mt genes
Histochemical
deficiency
COX ATPase
Biochemical deficiency
Respiratory chain complex
I + III
ND 1—6, subunits of NADH-dehydrogenase (complex I)
A 6/8, ATPase subunit 6 and 8, respectively
COX, cytochrome c oxidase
0, normal pattern (histochem.), no deficiency (biochem.)
+ , focal deficiency (histochem.), decreased enzyme activity (biochem.)
n.d., not determined
Respiratory chain complexes I + III, II 4- III, IV, for biochemical measurements see the method section
II + III IV
Group 1
1
2
3
4
5
Group 2
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Group 3
22
23
24
25
26
8286-14956
9000-13000
11680-14747
7867-14956
8286-13367
6070-14258
8640-13020
8286-13520
8640-13667
8867-14258
deletion not mapped
not mapped
not mapped
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
no larger mt deletion
A8 -
A5 -
ND4
ND6
ND 5
- ND6
COX II - Cytb
A 8 -
COX I
A6 -
A8 -
A6 -
A6 -
ND 5
- ND6
ND 5
ND 5
ND 5
ND 6
+ n.d.
+ n.d.
+ n.d.
+ n.d.
+ +
+ 0
+ +
+ n.d.
+ n.d.
+ n.d.
4- 4-
+ 0
-f- 4-
-|- +
+ 0
+ 0
n.d. n.d.
n.d. +
0
n.d.
n.d.
+ n.d.
+ n.d.
+ 0
n.d. n.d.
+ 0
+ + +
0 0 +
0 0 0
+ 0 +
n.d.
n.d.
n.d.
0 n.d. 0
+ 0 +
4- 0 +
0
n.d.
n.d.
n.d.
4- n.d. 0
+ 0 +
0
n.d.
n.d.
n.d.
n.d.
n.d.
+ 0 +
0 0 +
0 0 +
+ 0 +
0 0 0
Secondly, no lengthy deletions of the mtDNA have
so far been detected by restriction analysis in other
defined mitochondrial myopathies or encephalomyo-
pathies, such as myopathies with lactic acidosis, be-
nign or fatal infantile cytochrome c oxidase deficiency,
Luffs disease, mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes, myo-
clonus epilepsy with ragged red fibers (with the ex-
ception of 1. c. (5)) and others. Wallace (28) presented
considerable evidence for small mtDNA deletions in
myoclonus epilepsy with ragged red fibers. A point
mutation was observed in cases with Leber's opticus
atrophy (29).
Thirdly, usually a normal pattern for complex II ac-
tivity was found histochemically in muscles from pa-
tients with chronic progressive external ophthalmo-
plegia, with the exception of 1. c. (30). Exact histo-
chemical determination of NADH-dehydrogenase is
impossible, because the rotenone-sensitive (complex
I) and rotenone-insensitive activities (microsomal
fraction) cannot be separated by this technique. Focal
deficiency of complex IV activity was found in the
majority of patients with chronic progressive external
ophthalmoplegia, but also in patients suffering from
other forms of mitochondrial myopathy, indicating
defects in the nuclear-rmtochondrial axis. Histochem-
ical determination of cytochrome c oxidase therefore
seems to be a good screening method for all forms of
mitochondrial myopathy involving the respiratory
chain. ATPase activity was found to be deficient in
about 30-50% of the patients with mtDNA dele-
tions.
Fourthly, biochemical measurements of the different
complexes of the respiratory chain yielded decreased
activity only in 30 — 50% of patients with a deleted
mitochondrial genome. This is probably due to the
fact that in Kearns-Sayre syndrome and related dis-
orders focal defects affecting only single fibres are
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common. Overall activity measurements in tissue ho-
mogenates might therefore not reflect the situation,
because the number of affected cells is to small. Bio-
chemical measurements in muscle homogenates from
patients with chronic progressive external ophthal-
moplegia are therefore of minor diagnostic value.
Fifthly, as can be seen from table 2, in more than 50
percent of patients with chronic progressive external
ophthalmoplegia, restriction fragment analysis did
not detect any large mtDNA deletions. However this
does not necessarily mean that there were no mtDNA
mutations in these patients. For methodical reasons
detection of mutations by genomic Southern blotting
depends on a given length of the mutation (about 200
base pairs) and on a given number of mutated gen-
omes (about 5% of total mtDNA). If neither param-
eter attains its necessary value, restriction analysis
will yield false negative results. A convincing example
for this fact was given most recently by Sato et al.
(10). Using a primer shift polymerase chain reaction
the authors were able to demonstrate seven popula-
tions of differently deleted mtDNA (3.9-5.2 kb in
length) in a patient with chronic progressive external
ophthalmoplegia. In this patient a normal BamHI
and Pvull restriction pattern was found, his isolated
muscle mitochondria showed normal activities for all
respiratory chain complexes, and the Western blot
analysis of several subunits of the respiratory chain
complexes yielded a normal pattern. The authors
noted that the history of the patient's family suggested
maternal transmission of the disease.
Sixthly, the question of whether the large mtDNA
deletions found in patients with chronic progressive
external ophthalmoplegia are maternally transmitted,
1. e. inherited, or indeed genetic, but aquired during
the early state of development is of major importance
for genetic counselling. All of our 13 patients with
mtDNA deletions were singleton cases, while three
patients of group 2 without a mutated mitochondrial
genome had affected family members. Out of the 21
chronic progressive external ophthalmoplegia patients
with mtDNA heteroplasmy reported by Holt et al. (1,
2, 38) only two had a similarly affected relative, while
10 of their patients without deletions had clinically
affected family members, and maternal transmission
occurred in 50%. None of the 32 chronic progressive
external ophthalmoplegia cases with mtDNA deletion
described by Moreas et al. (7) had affected family
members, whereas approximately half (13/27) the pa-
tients with ocular myopathy but without detectable
mtDNA deletions had. Thus it seems evident that the
majority of chronic progressive external ophthalmo-
plegia patients with mtDNA deletions detectable by
restriction analysis and Southern botting are sponta-
neous singleton cases. There are three reports (4, 10,
31) dealing with inheritance of larger mtDNA dele-
tions. Ozawa et al. (4) described maternal inheritance
of non-identical mtDNA deletions in a mother/daugh-
ter pair. The same group reported (10) the case men-
tioned above with deletions only demonstrable after
amplification of the mitochondrial genome using the
polymerase chain reaction. Zeviani et al. (31) in a
most recent paper demonstrated an autosomal dom-
inant disorder with multiple deletions of mtDNA in
a large Italian family suffering from late-onset mito-
chondrial myopathy, including chronic progressive
external ophthalmoplegia, progressive proximal
weakness, bilateral cataract and precocious death.
This report demonstrated in an impressive way the
close cooperation between the nuclear genome and
the mtDNA in order to establish the highly organized
structure of the respiratory chain complexes.
As Kearns-Sayre syndrome and related diseases are
multisystem disorders the mtDNA deletions may not
be confined to skeletal muscle alone, but may affect
other tissues. Similar deletions to those in muscle have
been found in single cases in brain, liver, spinal cord,
primary fibroblasts and myoblast cultures as well as
in white blood cells (9, 11, 32, 33). While we were
able to detect an identical deletion, i. e. of equal size
and site, in skeletal muscle, heart, liver and kidney in
one Kearns-Sayre patient (34), we could find no cor-
responding mutations in fibroblast cultures or in white
blood cells from two others. Holt et al. (1, 2, 38) were
also unable to find deletions in the mtDNA of leu-
kocytes from their patients with deleted muscular
mitochondrial genome. This discrepancy or uneven
distribution of affected mitochondrial genomes in dif-
ferent tissues might be due to mitotic segregation (23)
during the early state of development of the oocyte
or the zygote, resulting in quite different proportions
of deleted genomes in the different tissues. Further-
more, the method of restriction analysis might not be
sensitive enough to detect small proportions of deleted
mtDNA. Amplification of the "hot spot" regions
within the mitochondrial genome by the polymerase
chain reaction (26, 27, 35) will probably solve the
question of whether white blood cells or fibroblasts
could serve for diagnosis.
Diagnostic procedures
With respect to the limited tissue material usually
available and taking into consideration the data in
the literature, we propose the diagnostic procedure
given in figure 4. The main conclusions regarding the
choice of diagnostic procedure are set out below.
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Diagnostic procedures for mitochondria! disorders
Myopathies with lactic
acidosis
Encephalomyopathies such as myoclonus epilepsy with
ragged red fibres (MERRF); mitochondrial encephalomyo-
pathy/lactic acidosis/stroke (MELAS); Leigh syndrome
Encephalomyopathies with chronic
progressive external ophthalmoplegia
Lactate in urine
Screening for organic acids in
urine, amino acids, ketone
bodies, carnitine in serum
Measurements of substrate
utilisation in isolated
mitochondria
ι
Muscle biopsy
Histology
Histochemistry
Immunhistochemistry
Electron microscopy
White blood cells, skin biopsy,
fibroblasts
Restriction fragment analysis
of the mitochondrial genome
by Pvu II and BamH I
Biochemical measurements in
muscle homogenates:
Pyruvate oxidation
Carnitine metabolism
-Oxidation
Krebs-Cycle
Respiratory chain
Complete mapping of the
mitochondrial genome
Fig. 4. Diagnostic procedures for mitochondrial disorders.
Tab. 3. Summary of muscular mtDNA deletions reported so far: update January 1990
Classification of disease
(reference)
Total number
of patients
Patients with
mtDNA heteroplasmy
in muscle
Patients with
mtDNA heteroplasmy
and familial history
Patients without
mtDNA heteroplasmy
and familial history
Kearns-Sayre syndrome (chronic progressive external ophthalmoplegia, retinitis pigmentosa,
(1, 2, 38)
(11)
(7)
(33)
(8)
(12, this study)
10
11
18
7
1
_5
52
Ocular myopathy (without Kearns-Sayre syndrome)
(1, 2, 38) 32
(7) 44
(6) 2
(8) 2
(9) 2
(10) 2
(12, this study) 16
98
Other mitochondrial myopathies*)
(1, 2, 38) 30
(7) 61
(5) 1
(this study) _5
97
11
15
6
1
_5
46
12
17
2
2
1
1
_8
43
0
0
1 (homoplasmy)
_Q
1
one additional symptom)
0
0
9
2
0
mother/daughter
0
?
i
ο
?
13
10
9
*) including: myoclonus epilepsy with ragged red fibres, mitochondrial encephalomyopathy/lactic acidosis/stroke, Leigh syndrome,
congenital lactic acidosis, benign and fatal cytochrome c oxidase deficiency, ATPase deficiency and other diseases without
chronic progressive external ophthalmoplegia
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— For exact defect localization, restriction analysis
and mapping of muscular mtDNA is superior to
histological, histochemical and biochemical methods
in patients with chronic progressive external ophthal-
moplegia. The latter methods provide confirmatory
evidence. In chronic progressive external ophthal-
moplegia cases with a family history of the disease, if
the restriction analysis using single cutter restriction
endonucleases gives a negative result, the mitochon-
drial genome fragments should be amplified by the
polymerase chain reaction. The same is true for other
mitochondrial disorders with maternal transmission,
where restriction analysis of the mtDNA so far failed
to detect any mutations. DNA techniques, which al-
low the detection of small or even point mutations
have been successfully applied in cases with Leber's
opticus atrophy (29), and these should also be used
for other patients.
— Histological, histochemical, immunological and
biochemical determinations are the methods of choice
for the time being for all spontaneous singleton cases
suffering from mitochondrial myopathies with lactic
acidosis as the leading symptom, since DNA tech-
niques at the level of the nuclear genome are still in
their infancy. With respect to the tissue specificity of
certain mitochondrial diseases, the existence and the
investigation of nuclear encoded isoforms, for exam-
ple of cytochrome c oxidase (36), will be of special
interest.
A closer cooperation between clinicians, biochemists
and molecular biologists is necessary in the near fu-
ture, in order to develop successful diagnostic proce-
dures for the different forms of mitochondrial disor-
ders. As noted by Wallace (87), a wide spectrum of
neuromuscular diseases has been shown to be influ-
enced by maternal factors. DNA techniques will un-
doubtedly soon identify other mtDNA genetic dis-
eases, ultimately replace biochemical and histochem-
ical procedures and lead to a better understanding of
the underlying principles of genetic mitochondrial dis-
orders.
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